


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-14.49%
-9.31%
+1.71%
-0.64%
-2.59%
NVO
Novo Nordisk A/S
$37.45
Strengths

Trading below its fair value

Expands stock buyback program

Upgraded on attractively valued

Outperform the market
Risk Analysis

Earnings are forecast to decrease
Technical Indicators

5+ Days Down
NVO Price Performance
$58.93 (-36.45%)
$47.57 (-21.27%)
$59.65 (-37.22%)
$80.15 (-53.28%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings
Earnings decline YoY
Above analyst estimates
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Expands stock buyback program
Investors confidence is positive
Future
Future
Earnings are forecast to decrease
Trading below its fair value
Outperform the market
NVO Analysts opinion is negative and has getting worse from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
NVO Street Sentiment is bullish and have positive views on the near-term outlook
NVO has Low risk level
Risk Indicators
Sentiments overview associated with events and the stock performance
Average key support and resistance price levels
Recent Upgrades and Downgrades
Jan 10, 2026
Initiate
Outperform
CICC
Dec 16, 2025
Upgrade
Buy
BERENBERG
Nov 29, 2025
Reiterate
Buy
Goldman Sachs
Nov 25, 2025
Initiate
Overweight
Nov 20, 2025
Reiterate
Buy
LLY
Eli Lilly and
1051.99
+2.93%
PFE
Pfizer
27.65
+2.03%
LEXX
Lexaria Bioscience
0.70
-2.71%
VKTX
Viking Therapeutics
33.84
+2.64%
SNY
Sanofi
48.66
+0.64%
What is NVO current stock price?
What are NVO stock strengths?
What is NVO Risk Level?
What is NVO market cap and volume?
What is NVO current Stock IQ?
Should I buy NVO stock right now?
Is NVO a Strong Buy right now?
What does a 'Strong Buy' rating mean for NVO?
What does a 'Strong Sell' rating mean for NVO?
What factors influence NVO's Stock IQ?
Join our subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
NVO
Novo Nordisk A/S
Current Price
$37.45
Runners Also Watch
LLY
Eli Lilly and
1051.99
+2.93%
PFE
Pfizer
27.65
+2.03%
LEXX
Lexaria Bioscience
0.70
-2.71%
VKTX
Viking Therapeutics
33.84
+2.64%
SNY
Sanofi
48.66
+0.64%

NVO Price Performance
$58.93 (-36.45%)
$47.57 (-21.27%)
$59.65 (-37.22%)
$80.15 (-53.28%)
NVO Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings
Earnings decline YoY
Above analyst estimates
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Expands stock buyback program
Investors confidence is positive
Future
Future
Earnings are forecast to decrease
Trading below its fair value
Outperform the market
NVO Analysts opinion is negative and has getting worse from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
NVO Street Sentiment is bullish and have positive views on the near-term outlook
NVO has Low risk level
Risk Indicators
Average key support and resistance price levels
Overall Wall Street Rating
NVO Stock IQ
Stock Insights
Strengths

Trading below its fair value

Expands stock buyback program

Upgraded on attractively valued

Outperform the market
Risk Analysis

Earnings are forecast to decrease
Technical Indicators

5+ Days Down
NVO Latest Analysis
Why Im Still ish On Novo Nordisk Despite Recent Setbacks.
Fri Feb 27, 2026
Thu Feb 26, 2026
Why is Novo Nordisk cutting GLP‑1 drug prices? #health. Rationale behind the price cuts and what it could mean Novo Nordisk announced plans to reduce United States list prices for its GLP‑1 diabetes and obesity medicines by up to 50% beginning in 2027. The company frames the move as a way to expand access to treatments that have seen explosive demand ease
Thu Feb 26, 2026
How will Novos GLP‑1 price cuts affect patients? #health. Price change could improve access for some not all Novo Nordisk has announced plans to cut list prices of its GLP‑1 diabetes and weight‑loss medicines in the United States by up to 50% with changes scheduled to start in 2027. The move is aimed at reducing costs for insured patients and addressing public
Thu Feb 26, 2026
Novo Nordisks 40% Fall May Be Creating A Deep-Value Moment. Novo Nordisk A/S (NYSE:NVO) has lost more than half its value from its peak. NVO stock is down 58% over the past year and more than 40% in just the past month collapsing from a 52-week high of $91.90 to near $38.But beneath the selloff something unusual has emerged.Novo Nordisk is no longer priced like a hypergrowth AI-era healthcare leader. It'.s priced like a slow-growth legacy pharma stock.NVO Stock Now Trades At A Fraction Of Pe
Wed Feb 25, 2026
How will Novo Nordisks price cuts affect access? #health. A major maker shrinks list prices — but access is complex Novo Nordisk announced plans to cut United States list prices for its GLP‑1 diabetes and weight‑loss drugs by as much as half starting in 2027. The move affects headline prices for products like Wegovy and Ozempic and comes amid fierce competition
Wed Feb 25, 2026
Novo Partners with Biotech Vivtex to Boost Obesity Drug Pipeline. Novo Nordisk A/S will partner with US biotech firm Vivtex Corp. to develop next-generation drugs for obesity diabetes and other metabolic diseases in a deal potentially worth up to $2.1 billion.
Wed Feb 25, 2026
FIND US ON
Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.